
Provention Bio PRVB
Quarterly report 2022-Q3
added 05-16-2026
Provention Bio Accounts Receivables 2011-2026 | PRVB
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Provention Bio
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.36 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.36 M | 1.36 M | 1.36 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
73.6 K | - | 5743.5 % | $ 69.7 M | ||
|
Happiness Biotech Group Limited
HAPP
|
11.4 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
17.8 M | $ 1.69 | 2.74 % | $ 198 M | ||
|
I-Mab
IMAB
|
130 M | - | - | $ 866 M | ||
|
Celldex Therapeutics
CLDX
|
2.02 M | $ 31.72 | 2.82 % | $ 2.11 B | ||
|
CRISPR Therapeutics AG
CRSP
|
25 M | $ 53.82 | 4.33 % | $ 4.84 B | ||
|
Compugen Ltd.
CGEN
|
61 M | $ 2.76 | 3.96 % | $ 258 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
28 K | $ 0.75 | 9.65 % | $ 34.3 M | ||
|
Esperion Therapeutics
ESPR
|
140 M | $ 3.13 | 0.16 % | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
11.8 M | $ 31.98 | 2.21 % | $ 861 M | ||
|
Berkeley Lights
BLI
|
18.5 M | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
1.22 M | - | - | $ 344 M | ||
|
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M | ||
|
Hutchison China MediTech Limited
HCM
|
127 M | $ 11.78 | 0.26 % | $ 10.1 B | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
97 K | - | - | $ 384 M | ||
|
Heron Therapeutics
HRTX
|
89.6 M | $ 0.9 | 1.45 % | $ 150 M | ||
|
ImmuCell Corporation
ICCC
|
3.42 M | $ 10.62 | 1.1 % | $ 95.9 M | ||
|
Anika Therapeutics
ANIK
|
23.7 M | $ 14.67 | -1.48 % | $ 210 M | ||
|
Advaxis
ADXS
|
234 K | - | -9.65 % | $ 45.9 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.7 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M |